Intranasal Delivery of miR133b in a NEO100-Based Formulation Induces a Healing Response in Spinal Cord-Injured Mice

Cells, 2023 · DOI: 10.3390/cells12060931 · Published: March 18, 2023

Simple Explanation

This study explores a new way to deliver medicine to the spinal cord after an injury. Instead of injecting drugs, the researchers used a nasal spray containing a molecule called miR133b. They also added a substance called NEO100 to help the drug get into the cells of the spinal cord. The study found that the nasal spray containing miR133b and NEO100 helped mice recover from spinal cord injuries. This method could be a practical and non-invasive alternative to intravenous administration that can be used in emergency situations.

Study Duration

8 Weeks

Participants

Seventy-five C57BL6 female mice

Evidence Level

Not specified

Key Findings

1
IN delivery of miR133b/Ago2 reaches the lesion scar and co-administration of miR133b with NEO100 facilitated the cellular uptake.
2
The study enhanced the motor function and addition of NEO100 potentiated this effect and targeted FN1 expression at the lesion scar.
3
IN delivery of either miR133b/Ago2 alone in a combination with NEO100 has the potential of delaying or preventing the full extent of regular scar formation.

Research Summary

The study investigates whether intranasal (IN) administration of miR133b/Ago2 can achieve a therapeutic effect on spinal cord injuries (SCI) in mice. The study also determines whether a NEO100-based formulation of miR133b/Ago2 can improve effectiveness. The study found that IN delivery of miR133b/Ago2 enhances motor function. The data supports that IN delivery of miR133b/Ago2 in a NEO100-based formulation further enhanced miR133b accumulation at the lesion scar.

Practical Implications

Novel Drug Delivery Method

Intranasal delivery of miR133b/Ago2 in a NEO100-based formulation is a promising non-invasive approach for treating spinal cord injuries.

Enhanced Therapeutic Efficacy

The use of NEO100 enhances the accumulation of miR133b at the lesion scar, leading to improved motor function recovery.

Potential Clinical Applications

This delivery method has the potential to be translated into clinical emergency situations following neurotrauma events.

Study Limitations

1
The studies are in young female mice.
2
Further pharmacokinetic studies are required to determine the mechanism of miR133b uptake in different cells present at the lesion scar.
3
The mechanism by which FN1 expression decreases upon IN administration of miR133b/Ago2 has not been investigated.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury